A.A. Kirshin1, V.M. Napolskikh2
1Udmurtia Cancer Center, Izhevsk
2Izhevsk State Medical Academy, Izhevsk
Kirshin A.A. ― head of the surgical department №1, oncologist of the Udmurtia Cancer Center
102 Lenin Str., Izhevsk, Russian Federation, 426009, tel. +7-912-467-52-79, e-mail: kirshinalex80@mail.ru
Abstract
Aim ― to study the oncological feasibility of using vascular technologies in parenchyma-sparing surgical treatment of lung cancer.
Material and methods. From 2009 to 2016, 92 consecutive patients underwent angioplastic lobectomies with resection and reconstruction of the pulmonary artery in non-small cell lung cancer. Men were 69 (75%), women ― 23 (25%), the average age was 57.8±6.7 years.
Results. There were no intraoperative complications or deaths. Postoperative complications occurred in 23 cases (25%). There were 3 (3.3%) deaths (30-day mortality). The overall one-year survival of patients with stage I-III lung cancer after angioplastic lobectomy was 96.7%, 3-year ― 65.1%, 5-year ― 36.6%, at median follow-up ― 53.1 months. Disease-free survival in I-III stages of lung cancer was: one-year ― 89.9%, three-year ― 65.3%, five-year ― 48.8%, at median follow-up was 49.8 months.
Conclusion. Angioplastic lobectomy is not only a technically feasible and safe procedure, but also provides promising long-term results. This confirms our opinion about the feasibility of this procedure for non-small cell lung cancer.
Key words: lung cancer, pulmonary artery resection, lobectomy, parenchima- sparing surgery.